The study was designed to determine whether SCH 530348, when added to the existing standard of care for preventing heart attack and stroke (eg, aspirin, clopidogrel) in patients with a known history of atherosclerosis, will yield additional benefit over the existing standard of care without SCH 530348 in preventing heart attack and stroke. The study was also designed to assess risk of bleeding with SCH 530348 added to the standard of care versus the standard of care alone.
MAIN RESULTS:
Vorapaxar in the secondary prevention of atherothrombotic events

N Engl J Med. 2012 Apr 12;366(15):1404-13.
PRESENTATIONS
Scientific Update: Latest Results from TRA 2°P-TIMI 50 (Webcast)
- Vorapaxar in Secondary Prevention (Morrow)
- Insights in Patients with PAD (Bonaca)
- High Risk Patients and Secondary Endpoints (Scirica)
Diabetes (Circulation 2015)
Approval Population (TCT 2014)
Polyvascular Disease (ACC 2013)
Stent Thombosis (AHA 2013)
Peripheral Artery Disease (AHA – ESS 2012)
Stroke (AHA 2012)
TRA2P-TIMI 50 CLI Cart Analysis (Bonaca, AHA 2019)
Lipoprotein(a) and the risk of Major Adverse Limb Events in Patients with Stable Atherosclerotic Vascular Disease (Bonaca, ESC 2023)
OTHER PUBLICATIONS